Collaboration agreement commercial milestones.

No definition available.

Name:	ck0002100782_CollaborationAgreementCommercialMilestones
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration agreement development and regulatory milestones.

+ References

No definition available.

+ Details

Name:	ck0002100782_CollaborationAgreementDevelopmentAndRegulatoryMilestones
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration agreement development milestones.

+ References

No definition available.

+ Details

Name:	ck0002100782_CollaborationAgreementDevelopmentMilestones
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration agreement eligible to receive potential milestone payments.

+ References

No definition available.

+ Details

Name:	ck0002100782_CollaborationAgreementEligibleToReceivePotentialMilestonePayments
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration arrangements upfront payment received.

+ References

No definition available.

+ Details

Name:	ck0002100782_CollaborationArrangementsUpfrontPaymentReceived
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cumulative adjustment to revenue.

+ References

No definition available.

+ Details

Name:	ck0002100782_CumulativeAdjustmentToRevenue
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Investment in equity

+ References

No definition available.

+ Details

Name:	ck0002100782_InvestmentInEquity
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payment Recognized.

+ References

No definition available.

+ Details

Name:	ck0002100782_MilestonePaymentRecognized
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Remaining fixed transaction price.

+ References

No definition available.

+ Details

Name:	ck0002100782_RemainingFixedTransactionPrice
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Transaction price

+ References

No definition available.

+ Details

Name:	ck0002100782_TransactionPrice
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Transaction price allocated to the target program.

+ References

No definition available.

+ Details

Name:	ck0002100782_TransactionPriceAllocatedToTheTargetProgram
Namespace Prefix:	ck0002100782_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense reimbursement, included in statement of income expense caption being disaggregated, from another entity related to cost-sharing or cost-reimbursement arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-26

+ Details

Name:	us-gaap_DisaggregationOfIncomeStatementExpenseCaptionReimbursementFromAnotherEntityAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense reimbursement, included in statement of income expense caption being disaggregated, to another entity related to cost-sharing or cost-reimbursement arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-28

+ Details

Name:	us-gaap_DisaggregationOfIncomeStatementExpenseCaptionReimbursementToAnotherEntityAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ck0002100782_NovartisCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=ck0002100782_SeriesCConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ck0002100782_AmgenCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_FirstTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_SecondTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_ThirdTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_FourthTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_FifthTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ck0002100782_SixthTargetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ck0002100782_AgreementWithTheUniversityOfTexasMDAndersonCancerCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ck0002100782_AgreementWithRoswellParkComprehensiveCancerCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Additional Information (Details) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 21, 2025	Sep. 19, 2024	Dec. 12, 2023	May 09, 2023	Oct. 05, 2022	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2024
Novartis Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments received		$ 50,000,000
Collaboration agreement development and regulatory milestones		130,000,000
Collaboration agreement commercial milestones		210,000,000
Transaction price		50,000,000
Revenue recognized under the Collaboration Agreement						$ 5,600,000	$ 6,700,000	$ 12,100,000	$ 13,400,000
Novartis Collaboration Agreement \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Eligible to receive potential milestone payments		$ 1,000,000,000
Novartis Collaboration Agreement \| Series C Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock sold in the collaboration		1,265,822
Amount received for stock sold in collaboration		$ 15,000,000
Amgen Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments received			$ 5,000,000		$ 50,000,000
Amount received for stock sold in collaboration				$ 25,000,000
Collaboration agreement development and regulatory milestones			160,000,000		160,000,000
Collaboration agreement commercial milestones			210,000,000		210,000,000
Investment in equity			25,000,000
Collaboration agreement development milestones										$ 5,000,000
Milestone payment recognized										$ 5,000,000
Remaining fixed transaction price	$ 4,300,000
Cumulative adjustment to revenue	$ 1,300,000
Revenue recognized under the Collaboration Agreement						$ 700,000	$ 3,400,000	1,400,000	$ 5,500,000
Amgen Collaboration Agreement \| First Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			9,200,000
Amgen Collaboration Agreement \| Second Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			10,400,000
Amgen Collaboration Agreement \| Third Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			9,200,000
Amgen Collaboration Agreement \| Fourth Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			9,000,000
Amgen Collaboration Agreement \| Fifth Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			9,500,000
Amgen Collaboration Agreement \| Sixth Target Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to the target program			7,700,000
Amgen Collaboration Agreement \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Eligible to receive potential milestone payments			$ 370,000,000		$ 370,000,000
Amgen Collaboration Agreement \| Series C Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock sold in the collaboration				2,109,704
MD Anderson \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net reimbursement payable								100,000
Roswell Park
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount reimbursed to company								$ 1,200,000